App-Quantinova.ai

PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: UPDATES FROM THE RESPOND CONSORTIUM

Hamed Akbari - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

THE DEEP TOPOLOGY OF GLIOMAS

James Ruffle - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

RAPID EARLY PROGRESSION (REP) OF GLIOBLASTOMA IS AN INDEPENDENT NEGATIVE PROGNOSTIC FACTOR: RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS

Mueez Waqar - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

MULTI-PARAMETRIC MRI-BASED MACHINE LEARNING ANALYSIS FOR PREDICTION OF NEOPLASTIC INFILTRATION AND RECURRENCE IN PATIENTS WITH GLIOBLASTOMA: UPDATES FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM

Hamed Akbari - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

IMPACT OF TUMOUR CHARACTERISTICS AND CANCER TREATMENT ON CEREBROVASCULAR MORTALITY AFTER GLIOMA DIAGNOSIS: EVIDENCE FROM A POPULATION-BASED CANCER REGISTRY

Paul Brennan - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

STEREOTACTIC RADIOSURGERY (SRS) FOR BRAIN METASTASES FROM MELANOMA: AN EVALUATION OF OUTCOMES AT A UK TERTIARY CENTRE

Puteri Abdul Haris - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

LEEDS LOW GRADE GLIOMA SERVICE 2010-2022: A 12-YEAR EXPERIENCE

Neeraj Kalra - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Low-grade gliomas

N/A

FAMILY CAREGIVER CONSTRUCTS AND OUTCOMES IN NEURO-ONCOLOGY: A SYSTEMATIC REVIEW

Florien Boele - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral metastases

N/A

AN ANTISENSE OLIGONUCLEOTIDE AGAINST TUMOR MICROTUBES IN GLIOBLASTOMA AS A NEW THERAPEUTIC OPTION TO IMPROVE TUMOR SPECIFIC THERAPY

Sophie Weil - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

TELOMERASE INHIBITION IS AN EFFECTIVE THERAPEUTIC STRATEGY IN TERT PROMOTER-MUTANT GLIOBLASTOMAS MODELS WITH LOW TUMOR BURDEN

Lauren Kageler - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Doxycycline

INHIBITION OF THE ANGIOTENSIN II TYPE 2 RECEPTOR AT2R IS A NOVEL THERAPEUTIC STRATEGY FOR GLIOBLASTOMA

Richard Perryman - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Angiotensin II

COMBINED PHARMACOLOGICAL AND GENETIC SCREENING TO IDENTIFY DEPENDENCIES AND COMBINATIONS IN ACVR1-MUTANT DIFFUSE MIDLINE GLIOMA

Rebecca Rogers - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Everolimus

HDAC INHIBITOR, CAY10603, IS A POTENT RADIOSENSITIZER IN MENINGIOMAS

Clemens Oliver Hanemann - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

N/A

AN INNOVATIVE APPROACH TO ACCESSIBLE INFORMATION FOR BRAIN TUMOUR PATIENTS AND THEIR LOVED ONES

Victoria Hurwitz - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

High-Grade Gliomas

N/A

IDENTIFYING RISK FACTORS FOR PROLONGED TRANSFUSION-DEPENDENT TEMOZOLOMIDE-INDUCED THROMBOCYTOPAENIA IN PATIENTS RECEIVING CONCURRENT CHEMO-RADIOTHERAPY FOR GLIOBLASTOMA (GBM)

Nashwah Ismail - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

EVALUATION OF INTRA-OPERATIVE BRAIN TUMOUR DIAGNOSTIC SERVICES – A LARGE TERTIARY UK CENTRE EXPERIENCE

Richard Digby - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral metastases

N/A

COMMUNICATION IN THE CONTEXT OF GLIOBLASTOMA TREATMENT: WHAT MATTERS MOST

Florien Boele - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

RETURNING TO WORK AFTER A BRAIN TUMOUR – “I THOUGHT I WOULD BE BACK AT WORK THE NEXT WEEK, HOW WRONG I WAS!”

Emma Nicklin - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral metastases

N/A

CAN NEOADJUVANT CHEMOTHERAPY INCREASE EXTENT OF RESECTION IN DIFFUSE LOWER-GRADE GLIOMA?

Piravin Ramakrishnan - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

MITOCHONDRIAL AND GENE EXPRESSION CHANGES IN BRAIN TUMOR CELLS GROWN IN Β-HYDROXYBUTYRATE

Ahmad Kareem Almekkawi - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

Filters

45280 Abstracts